Fig. 7: IL-22 is essential for the protective effects of urolithin A against colitis.

A Schematic outline of the experimental design. B–D Colitis severity was measured as body weight loss, DAI, and colon length (n = 8). E, F H&E staining of colon tissue and histological scores at day 8 after oral urolithin. G, H Secretion of TNF-α, IL-1β, IL-6 and IL-22 in serum, and the levels of TNF-α, IL-1β and IL-6 in colon homogenates. I Mice were intraperitoneally injected with anti-IgG2a or anti-IL22, and urolithin A was given to mice by oral gavage on day 3 of the DSS colitis model. J–L Disease severity was measured as body weight loss, DAI, and colon length (n = 8). M Flow cytometry of RORγ + IL22+ innate lymophoid cell populations from urolithin A-administrated mice at day 8 after DSS challenge. Data represent means ± SD of three separate experiments. Statistics was performed with unpaired two- sided Student’s t test or one-way ANOVA, followed by Tukey’s multiple comparison test. *P < 0.05, **P < 0.01.